Spondyloarthritis & psoriatic arthritis
Adherence to therapy of ixekizumab and secukinumab in psoriatic arthritis patients using first- or second-line IL-17A inhibitor treatment: a Danish population-based cohort study
Authors' conclusion
PsA patients receiving first- or second-line IL-17A inhibitors showed homogeneous baseline characteristics and similar adherence to therapy.
Study context
- Population
- PsA patients in DANBIO, 2014–2021, previously treated with one or more TNFi, receiving first- or second-line IL-17A inhibitor
- Participants
- 534 / 510 / 24 / 102 / 35 / 67
- Exposure
- First-line vs second-line IL-17A inhibitor treatment
- First-line switchersn = 534reference
- First-line secukinumabn = 510
- First-line ixekizumabn = 24
- Second-line switchersn = 102
- Second-line secukinumabn = 35
- Second-line ixekizumabn = 67
- Outcome
- Adherence to therapy (Kaplan-Meier)
Methodological detailsregistry-based (DANBIO), Kaplan-Meier analysis
- Registry-based (DANBIO)
- Kaplan-Meier analysis
Main finding
As reported in the abstract
Adherence to therapy
- First- and second-line switchers had a similar adherence to therapy
- Second-line secukinumab and second-line ixekizumab switchers showed a similar adherence to treatment
Observational data: associations, not effects.
Further findings
Baseline characteristics
- Similar HAQ and visual analogue scale (VAS) pain
- VAS global, DAS28-CRP and previous number of bDMARDs similar, with a greater value for second-line switchers
- First-line ixekizumab: younger age, more females, lower disease duration and lower CRP
- Concomitant MTX use greater for first-line secukinumab
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Adherence to therapy of ixekizumab and secukinumab in psoriatic arthritis patients using first- or second-line IL-17A inhibitor treatment: a Danish population-based cohort study. Rheumatology (Oxford). Published 30 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →